Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.37 |
| ▸ | ERBB2 | P04626 | 11/20 | 0.37 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.33 |
| ▸ | FECH | P22830 | 1/20 | 0.33 |
| ▸ | MYH14 | Q7Z406 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.33 |
| ▸ | TEC | P42680 | 1/20 | 0.33 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.33 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29309704 | 0.92 | EGFR (0.37) | EGFRERBB2BRAF | |
| SCHEMBL29309600 | 0.90 | ERBB2 (0.39) | EGFRERBB2RIPK3NQO2FECH | |
| SCHEMBL29309592 | 0.90 | EGFR (0.42) | EGFRERBB2RIPK3NQO2FECH | |
| SCHEMBL29309590 | 0.90 | EGFR (0.42) | EGFRERBB2RIPK3NQO2FECH | |
| SCHEMBL26895583 | 0.83 | EGFR (0.40) | EGFRERBB2RIPK3NQO2FECH | |
| SCHEMBL29309595 | 0.83 | EGFR (0.40) | EGFRERBB2RIPK3NQO2FECH | |
| SCHEMBL26896478 | 0.83 | EGFR (0.40) | EGFRERBB2RIPK3NQO2FECH | |
| SCHEMBL29309706 | 0.83 | EGFR (0.41) | EGFRERBB2RIPK3NQO2FECH | |
| SCHEMBL29309582 | 0.83 | ERBB2 (0.41) | EGFRERBB2RIPK3NQO2FECH | |
| SCHEMBL29309599 | 0.83 | ERBB2 (0.41) | EGFRERBB2RIPK3NQO2FECH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | NUVALENT, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037346-B2 | Amino-substituted heteroaryls for treating cancers with EGFR mutations | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885RIPK3 4270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.